Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study

被引：11

作者：

Marouf, Amira ^{[1
,2
,3
]}

Cottereau, Anne Segolene ^{[2
,4
]}

Kanoun, Salim ^{[5
]}

Deschamps, Paul ^{[1
,2
]}

Meignan, Michel ^{[6
,7
]}

Franchi, Patricia ^{[1
,2
]}

Sibon, David ^{[8
,9
]}

Antoine, Clara ^{[6
]}

Gastinne, Thomas ^{[10
]}

Borel, Cecile ^{[11
]}

Hammoud, Mohammad ^{[12
]}

Sicard, Guillaume ^{[13
]}

Gille, Romane ^{[14
]}

Cavalieri, Doriane ^{[15
]}

Stamatoullas, Aspasia ^{[16
]}

Filliatre-Clement, Lauriane ^{[16
]}

Lazarovici, Julien ^{[17
]}

Chauchet, Adrien ^{[18
]}

Fornecker, Luc-Matthieu ^{[19
,20
,21
]}

Amorin, Sandy ^{[22
]}

Rocquet, Mathieu ^{[1
]}

Raus, Nicole ^{[23
,24
]}

Burroni, Barbara ^{[25
,26
]}

Rubio, Marie Therese ^{[24
,27
,28
]}

Bouscary, Didier ^{[1
,2
,29
]}

Quittet, Philippe ^{[30
]}

Casasnovas, Rene Olivier ^{[31
,32
]}

Brice, Pauline ^{[33
]}

Ghesquieres, Herve ^{[34
]}

Tamburini, Jerome ^{[1
,2
,29
,35
]}

Deau, Benedicte ^{[1
,2
]}

机构：

[1] Hop Cochin, AP HP, Dept Hematol, Paris, France

[2] Univ Paris, Paris, France

[3] INSERM, UMR 1163, Inst Imagine, Paris, France

[4] Hop Cochin, AP HP, Dept Nucl Med, Paris, France

[5] INSERM, Canc Res Ctr Toulouse CRCT, Team 9, UMR 1037, Toulouse, France

[6] Hop Henri Mondor, Lymphoma Study Assoc Imaging, Lymphoma Acad Res Org LYSARC, Creteil, France

[7] Paris Est Univ, Creteil, France

[8] Necker Univ Hosp, Hematol Dept, AP HP, Paris, France

[9] Necker Univ Hosp, Inst Necker Enfants Malades, AP HP, INSERM U1151, Paris, France

[10] Nantes Univ Hosp, Dept Hematol, Nantes, France

[11] Inst Univ Canc Toulouse Oncopole, Dept Hematol, Toulouse, France

[12] Hop Henri Mondor, Lymphoid Malignancies Unit, Creteil, France

[13] Aix Marseille Univ, Dept Hematol, Marseille, France

[14] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[15] Ctr Hosp Univ CHU Estaing, Dept Hematol, Clermont Ferrand, France

[16] Clin Louis Pasteur, Dept Hematol, Nancy, France

[17] Inst Gustave Roussy, Dept Hematol, Villejuif, France

[18] CHU Besancon, Dept Hematol, Besancon, France

[19] Strasbourg Univ Hosp, Strasbourg, France

[20] INSERM S 1113, Strasbourg, France

[21] Strasbourg Univ, Fac Med, Strasbourg, France

[22] Hop St Vincent de Paul, Dept Hematol, Lille, France

[23] Hop Lyon Sud, Dept Hematol, Pierre Benite, France

[24] Soc Francophone Greffe Moelle & Therapie Cellulai, Pierre Benite, France

[25] Hop Cochin, AP HP, Serv Pathol, Paris, France

[26] Paris Univ, Sorbonne Univ, INSERM, Ctr Rech Cordeliers, Paris, France

[27] Hop Brabois, CHRU Nancy, Dept Hematol, Nancy, France

[28] Biopole Univ Lorraine, CNRS UMR 7365, Equipe 6, Vandoeuvre Les Nancy, France

[29] INSERM, Inst Cochin, U1016, Paris, France

[30] Univ Montpellier, Dept Hematol, Montpellier, France

[31] Dijon Univ Hosp, Dept Hematol, Dijon, France

[32] CHU Dijon, INSERM UMR 1231, Dijon, France

[33] Hop St Louis, CHU Paris GH St Louis Lariboisiere F Widal, Dept Hematol, Paris, France

[34] Ctr Hosp Lyon Sud, Dept Hematol, Pierre Benite, France

[35] Univ Geneva, Fac Med, Translat Res Ctr Oncohematol, Geneva 4, Switzerland

来源：

HAEMATOLOGICA | 2022年 / 107卷 / 07期

关键词：

THERAPY; COMBINATION; 2ND-LINE;

D O I：

10.3324/haematol.2021.279564

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1681 / 1686

页数：6

共 50 条

[1] Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation
Kaloyannidis, Panayotis
Hertzberg, Mark
Webb, Kate
Zomas, Athanasios
Schrover, Rudolf
Hurst, Michael
Jacob, Ian
Nikoglou, Thalia
Connors, Joseph M.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (04) : 540 - 549
[2] Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland
Parker, Christopher
Woods, Beth
Eaton, James
Ma, Esprit
Selby, Ross
Benson, Eugene
Engstrom, Andreas
Sajosi, Peter
Briggs, Andrew
Bonthapally, Vijayveer
JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (01) : 8 - 18
[3] ALLOGENEIC STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A MULTICENTER EXPERIENCE
Festuccia, M.
Busca, A.
Zallio, F.
Sorasio, R.
Brunello, L.
Maffini, E.
Dellacasa, C.
Passera, R.
Iovino, G.
Aydin, S.
Mordini, N.
Pini, M.
Boccadoro, M.
Bruno, B.
Giaccone, L.
HAEMATOLOGICA, 2016, 101 : 320 - 320
[4] Combination of Brentuximab Vedotin and Pembrolizumab as Salvage Treatment Before Autologous Stem Cell Transplantation and Maintenance in Patients with Relapsed/Refractory Hodgkin Lymphoma
Massa, Hanne
Massaro, Fulvio
Maerevoet, Marie
BIOMEDICINES, 2025, 13 (02)
[5] Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
Forlenza, Christopher J.
Rosenzweig, Jaclyn
Mauguen, Audrey
Buhtoiarov, Ilia
Cuglievan, Branko
Dave, Hema
Deyell, Rebecca J.
Flerlage, Jamie E.
Franklin, Anna K.
Krajewski, Jennifer
Leger, Kasey J.
Marks, Lianna J.
Norris, Robin E.
Pacheco, Martha
Willen, Faye
Yan, Adam Paul
Harker-Murray, Paul D.
Giulino-Roth, Lisa
BLOOD ADVANCES, 2023, 7 (13) : 3225 - 3231
[6] POST TRANSPLANT OUTCOMES IN A MULTICENTER PHASE II STUDY OF BRENTUXIMAB VEDOTIN AS FIRST LINE SALVAGE THERAPY IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION
Herrera, A.
Palmer, J.
Martin, P.
Armenian, S.
Tsai, N. -C.
Mott, M.
Sahebi, F.
Cai, J. -L.
Siddiqi, T.
Popplewell, L.
Nademanee, A.
Rosen, S.
Kwak, L.
Forman, S.
Chen, R.
HAEMATOLOGICA, 2016, 101 : 47 - 48
[7] COMPARING BRENTUXIMAB VEDOTIN OVERALL SURVIVAL DATA TO STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL) POST-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)
Woods, B.
Thompson, J.
Barcena, L.
Liu, Y.
Huang, H.
Martinez, C.
VALUE IN HEALTH, 2012, 15 (07) : A509 - A509
[8] Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma
Carmen Martínez
Manuel Espeso de Haro
Samuel Romero
Antonio Gutiérrez
Eva Domingo-Domènech
Ana P. González-Rodríguez
Izaskun Zeberio
María Paz Martínez-Badas
Antonia Rodríguez-Izquierdo
Cecilia Carpio
Mariana Bastos-Oreiro
José Ángel Hernández-Rivas
Rolando Vallansot
Nicholas Kelleher
Francisco J. Díaz-Gálvez
Tamara Torrado
Arturo Pereira
Ramón García-Sanz
Annals of Hematology, 2023, 102 : 429 - 437
[9] Brentuximab Vedotin Salvage Followed by Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in High Risk Relapsed Refractory Hodgkin Lymphoma
Damlaj, Moussab
Alaskar, Ahmed
Alahmari, Bader
Ghazi, Samer
Hejazi, Ayman
Alzahrani, Mohsen
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S233 - S233
[10] Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data
Bonthapally, Vijayveer
Wu, Eric
Macalalad, Alexander
Yang, Hongbo
Shonukan, Oluwatoyin
Liu, Yi
Chi, Andy
Huebner, Dirk
CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (05) : 993 - 1001

← 1 2 3 4 5 →